In the past year the pharmaceutical industry has witnessed an unprecedented number of drug recalls following the discovery that these products contained impurities, some of which are life t
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh